Trial Profile

A Prospective, Open-label, Single Center, Dose Finding Phase I-study With Atu027 (an siRNA Formulation) in Subjects With Advanced Solid Cancer.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 May 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATU 027 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Silence Therapeutics AG

Most Recent Events

01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
06 Jun 2012 Enrolment in the tenth and final dose cohort has been completed and the final treatment is scheduled for 22 June 2012.
06 Jun 2012 Results were reported at the 48th Annual Meeting of the American Society of Clinical Oncology, and in a Silence Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com